期刊文献+

《AGA关于难治性幽门螺杆菌感染管理的临床实践更新》解读 被引量:4

Interpretation of ″AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection:Expert Review″
下载PDF
导出
摘要 新近发表的《AGA关于难治性幽门螺杆菌感染管理的临床实践更新》包含以下两方面:(1)概述幽门螺杆菌(Helicobacter pylori,H.pylori)根除治疗失败的影响因素,包括目前所了解的宿主、微生物和系统相关的因素;(2)利用这些数据为临床医师提供基于证据和共识的多模式最佳实践建议,用于治疗首次根除失败后的H.pylori感染。本文对这些内容进行详细解读。 Recently published paper titled ″AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection:Expert Review″ includes the following two aspects:(1) provide a salient overview of causes of Helicobacter pylori(H.pylori) eradication treatment failure,including host-,microbe-,and systems-related factors;(2) leverage these data to provide clinical practitioners with evidence-and consensus-based multimodal best practice advice for treating H.pylori after the first treatment failure.Detailed interpretations of these 2 aspects were performed in this paper.
作者 董昀凡 张振玉 DONG Yunfan;ZHANG Zhenyu(Department of Gastroenterology,Nanjing First Hospital,Nanjing Medical University,Nanjing 210006,China)
出处 《胃肠病学和肝病学杂志》 CAS 2022年第5期487-491,共5页 Chinese Journal of Gastroenterology and Hepatology
关键词 幽门螺杆菌 难治性 管理 Helicobacter pylori Refractory Management
  • 相关文献

参考文献5

二级参考文献30

  • 1曹勤,冉志华,萧树东.血清胃蛋白酶原、胃泌素-17和幽门螺杆菌IgG抗体筛查萎缩性胃炎和胃癌[J].胃肠病学,2006,11(7):388-394. 被引量:113
  • 2刘文忠,吕宝妹,萧树东,徐蔚文,施尧,张德中.含克拉霉素的短程三联疗法根除幽门螺杆菌[J].中华内科杂志,1996,35(12):803-806. 被引量:41
  • 3Chao‐HungKuo,Sophie S.W.Wang,Wen‐HungHsu,Fu‐ChenKuo,Bi‐ChuangWeng,Chia‐JungLi,Ping‐IHsu,AngelaChen,Wen‐ChunHung,Yuan‐ChiehYang,Wen‐MingWang,Deng‐ChyangWu.Rabeprazole Can Overcome the Impact of CYP2C19 Polymorphism on Quadruple Therapy[J].Helicobacter.2010(4)
  • 4Chao-Hung Kuo,Fu-Chen Kuo,Huang-Ming Hu,Chung-Jung Liu,Sophie S. W. Wang,Yen-Hsu Chen,Ming-Chia Hsieh,Ming-Feng Hou,Deng-Chyang Wu,Ping-I Hsu.The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012[J].Gastroenterology Research and Practice.2012
  • 5Hao Li,Ling Meng,Fei Liu,Ji-Fu Wei,Yong-Qing Wang.H<sup>+</sup>/K<sup>+</sup>-ATPase inhibitors: a patent review[J].Expert Opinion on Therapeutic Patents.2013(1)
  • 6Kyung-Ah Seo,So-Jeong Lee,Kwon-Bok Kim,Soo Kyung Bae,Kwang-Hyeon Liu,Dong-Hyun Kim,Jae-Gook Shin.Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5[J].Xenobiotica.2012(3)
  • 7Dolores Serrano,Susana Torrado,Santiago Torrado-Santiago,Javier P. Gisbert.The Influence of CYP2C19 Genetic Polymorphism on the Pharmacokinetics/- Pharmacodynamics of Proton Pump Inhibitor-Containing Helicobacter pylori Treatments[J].Current Drug Metabolism.2012(9)
  • 8Krisztina Hagym&aacute,si,Katalin M&uuml,llner,L&aacute,szl&oacute,Hersz&eacute,nyi,Zsolt Tulassay.Update on the pharmacogenomics of proton pump inhibitors[J].Pharmacogenomics.2011(6)
  • 9Choon‐SengQUA,JeetaMANIKAM,Khean‐LeeGOH.Efficacy of 1‐week proton pump inhibitor triple therapy as first‐line Helicobacter pylori eradication regime in Asian patients: Is it still effective 10 years on?[J].Journal of Digestive Diseases.2010(4)
  • 10Shaojun Shi,Ulrich Klotz.Proton pump inhibitors: an update of their clinical use and pharmacokinetics[J].European Journal of Clinical Pharmacology.2008(10)

共引文献1709

同被引文献27

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部